Cybin's Clinical Leadership to Present at Healthcare Innovation Conference Amid Phase 3 Mental Health Drug Development

Cybin Inc., a Phase 3 clinical stage neuropsychiatry company, announced that Chief Business Officer George Tziras will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference scheduled for November 10-12, 2025, in Boston, Massachusetts. The company, which trades on both the NYSE American and Cboe CA under the symbol CYBN, focuses on transforming mental healthcare through proprietary drug discovery and delivery technologies. This conference participation comes as Cybin advances its clinical pipeline, including CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, potentially accelerating its development timeline.

The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. Cybin's research pipeline includes additional investigational compounds focused on 5-HT receptors, targeting the large unmet need for effective mental health treatments. The company's approach to developing novel drugs aims to provide effective and durable results for patients suffering from mental health conditions. Founded in 2019, Cybin maintains operations in Canada, the United States, the United Kingdom and Ireland, positioning itself as a global player in the neuropsychiatry space. The latest news and updates relating to CYBN are available in the company's newsroom at https://ibn.fm/CYBN.

Cybin's participation in the Guggenheim conference represents an opportunity to showcase its clinical progress and proprietary technologies to the investment community during a period of significant advancement in its lead programs. The company's focus on developing next-generation treatment options comes at a time when mental healthcare faces substantial challenges in providing effective, lasting solutions for conditions affecting millions worldwide. The full press release about the conference participation can be viewed at https://ibn.fm/uqBYE. InvestorWire, the platform that disseminated this announcement, provides specialized communications services including wire-grade press release syndication and social media distribution through its parent company IBN's network of millions of social media followers.

This conference appearance matters because it occurs as Cybin's lead program CYB003 progresses through Phase 3 clinical trials with Breakthrough Therapy Designation, indicating the FDA recognizes its potential to address serious conditions where current treatments are inadequate. The implications extend beyond investor relations to the broader mental healthcare landscape, where innovative treatments are urgently needed. Cybin's proprietary deuterated compounds represent a novel approach to psychedelic-inspired therapeutics that could offer improved safety profiles and treatment outcomes. The company's global operations and multiple clinical programs position it to potentially impact treatment paradigms for depression, anxiety, and other neuropsychiatric conditions that affect hundreds of millions worldwide.

The timing of this presentation is significant given increasing recognition of mental health as a global health priority and growing investment in psychiatric drug development. Cybin's technologies could help address the limitations of current antidepressant and anxiolytic medications, which often provide incomplete relief and carry significant side effects. The company's participation in a major healthcare innovation conference provides visibility for its scientific approach during a period of heightened interest in mental health therapeutics. As mental healthcare systems worldwide struggle with treatment gaps and limited options, Cybin's clinical progress represents potential advancement toward more effective interventions for some of the most challenging psychiatric conditions.